BlackRock's IHE and IYH offer distinct paths for healthcare exposure, with IHE's concentrated pharmaceutical focus currently outperforming the broader, more diversified IYH in recent market cycles.
Top holding in both iShares U.S. Healthcare ETF and iShares U.S. Pharmaceuticals ETF, being compared for 2026 investment.
Top holding in both iShares U.S. Healthcare ETF and iShares U.S. Pharmaceuticals ETF, being compared for 2026 investment.
Top holding in iShares U.S. Healthcare ETF, mentioned in article comparing healthcare ETFs.
Top holding in iShares U.S. Pharmaceuticals ETF, mentioned in article comparing healthcare ETFs.
Mentioned as the parent company of iShares which manages the discussed ETFs.
Investors weighing healthcare exposure are evaluating the iShares U.S. Pharmaceuticals ETF (IHE) against the broader iShares U.S. Healthcare ETF (IYH). While both funds share identical 0.37% expense ratios and BlackRock management, they differ in concentration and historical performance. IHE currently leads in recent annualized returns, making it a focal point for portfolio allocation strategies heading into 2026.
The primary difference is scope: IHE is a concentrated fund focused strictly on the pharmaceutical industry, whereas IYH is a broader basket that includes medical devices, biotechnology, and healthcare providers.